Primary systemic anaplastic lymphoma kinase (ALK)-negative anaplastic large-cell lymphoma (ALCL) has a poor prognosis. This study sought to determine if high-dose therapy and ASCT results in long-term diseasefree survival (DFS) in patients with recurrent, chemotherapy-sensitive ALK-negative ALCL. All patients with non-Hodgkin's lymphoma (NHL) who underwent ASCT at Wake Forest University and Upstate Medical University from 1 January 1990 to 12 December 2002 were reviewed to determine if they had T-, B-or null-cell NHL that was CD30 þ /CD15À/ALK negative. In all, 16 patients were thus identified as having ALK-negative ALCL. All 16 patients underwent ASCT at the time of first relapse and form the basis of this report. Median age of the 16 patients was 51 years. There were 11 males and five females. International prognostic index scores in 12 patients at the time of relapse were: low 3, LI 6 and HI 3. Of 15 patients, 13 relapsed after ASCT; one patient was lost to follow-up. Median progression-free survival for the 15 patients was 12 weeks (3-212 þ weeks). Of 15 patients, 10 have died; nine of recurrent disease. Median overall survival for the 15 evaluable patients was 72 weeks. In our experience, high-dose therapy and ASCT does not produce long-term DFS in patients with recurrent chemotherapy-sensitive ALKnegative ALCL.
Primary systemic anaplastic large-cell lymphoma (ALCL) is a morphologically variable non-Hodgkin's lymphoma (NHL) defined by cell surface expression of the cytokine receptor CD30 with either a T-cell or a null-cell immunophenotype on the neoplastic cells. 1, 2 Primary systemic ALCL is often associated with a translocation involving chromosomes 2;5, resulting in the nucleophosmin (NPM) gene located at 5q35 fusing with a gene at 2p23, which encodes the receptor tyrosine kinase, designated the anaplastic lymphoma kinase (ALK). 1, 2 The translocation results in an NPM-ALK fusion protein that constitutively activates the ALK tyrosine kinase. Monoclonal antibodies that react with fixative-resistant epitopes on the cytoplasmic tail of the ALK protein have allowed for retrospective analysis from archival paraffin-embedded tissue for NPM-ALK fusion protein expression in patients with ALCL.
Approximately 50-80% of patients with ALCL have tumors that express the ALK protein by immunohistochemistry. 3, 4 The determination of whether a primary systemic ALCL expresses the ALK protein is of prognostic significance, as patients with ALK-positive tumors have a much better survival than patients with ALK-negative tumors, despite both groups being treated with anthracycline containing combination chemotherapies. 5, 6 ALKpositive tumors tend to occur in younger patients, mostly in adolescents and young adults, but the prognostic significance of ALK expression may be independent of age. [5] [6] [7] For patients with ALCL who relapse after initial therapy, high-dose therapy and autologous stem cell transplant (ASCT) has a high degree of success in patients with chemotherapy-sensitive relapse. [7] [8] [9] However, in the reported series of patients to date with recurrent ALCL who have undergone high-dose therapy and autologous stem transplant, there has been no determination of ALK status of the patients' tumors. Since the majority of patients with primary systemic ALCL have tumors that express ALK, it can be assumed that the majority of the patients reported in these series would have ALK-positive tumors.
The present study was an attempt to determine if highdose therapy and ASCT could successfully salvage patients with recurrent ALK-negative ALCL.
Patients and methods
The records of all patients with NHL who underwent an ASCT at Wake Forest University and Upstate Medical University between 1 January 1990 and 12 December 2001 were reviewed. All patients had a diagnostic pathology report in the permanent record. Patients with a pathology report describing either follicular lymphoma or a documented B-cell lymphoma were excluded from further review. Reports describing a diffuse lymphoma NOS, Tcell, null-cell or CD30 þ lymphoma were further examined. In patients with diffuse lymphoma NOS, or T-cell/ null cell tumors, or patients with CD30 þ /CD15À tumors, paraffinembedded tissue blocks were obtained. Routine hematoxylin and eosin (H and E) -stained slides were reviewed from the WFU-BMC and the Upstate Medical University Pathology Departments files. Paraffin immunohistochemical studies were performed using standard techniques on an automated immunostainer (Ventana Medical System, Tucson, AZ, USA). The antibody panel consisted of CD20 (L26), EMA and ALK-1 protein (Dako, Carpinteria, CA, USA); CD3 (Ventana); CD30 (Novocastra, Newcastle Upon Tyne, UK); CD15 and CD43 (Beckton-Dickenson, San Jose, CA, USA). 10 The pathologic diagnoses in all cases were confirmed using current morphologic and phenotypic criteria. 10 In all, 16 patients were found who had a CD30 þ /T/null-cell ALK-negative tumor and form the basis of this study.
Retrospective chart reviews of the 16 patients were performed. Progression-free survival (PFS) and overall survival were determined from the day of autologous transplant until the day of relapse or death. Time to disease progression was determined from the dates of autologous stem transplant and the dates of computerized tomography reports and/or biopsy reports indicative of disease progression following ASCT. Kaplan-Meier methods were used to estimate disease-free survival (DFS) and overall survival. The international prognostic index (IPI) as originally described, utilizing age 460 years, elevated LDH, Ann Arbor Stage III/IV, performance status 42 and 41 extranodal site, as adverse prognostic variables was determined, where the data were available, at both diagnosis, and at the time of relapse prior to the start of salvage therapy. 11 The IPI has been shown to have prognostic significance in patients with peripheral T-cell lymphoma. 12 The 16 patients forming the basis for this report represent all patients with ALK-negative ALCL at the two institutions who underwent ASCT during this time period. All patients received anthracycline-based therapy as part of their initial therapy at diagnosis, and all received at least one cycle of salvage therapy at the time of relapse.
Results
In all, 16 patients with recurrent ALK-negative ALCL underwent high-dose therapy and ASCT. All patients received anthracycline containing combination therapy for their initial therapy. Patient demographics, disease characteristics at the time of initial diagnosis, as well as at relapse and after pre-transplant salvage therapy are summarized in Table 1 .
No patient in whom the IPI could be determined had a high (H) IPI score at relapse. Eight patients achieved a definite CR after salvage chemotherapy; one patient had a CR U and six patients had a PR. The transplant conditioning therapies for the 16 patients were: cyclophosphamide þ total body irradiation (eight patients), cyclophosphamide þ thiotepa þ etoposide (four patients), cyclophosphamide þ carmustine þ etoposide (two patients), cyclophosphamide þ busulfan (one patient) and cyclophosphamide þ etoposide þ total body irradiation (one patient). There was no transplant-related mortality in this series of 16 patients.
At the time of first reassessment post transplant, eight patients were in CR, five patients had a PR and three patients failed to respond to high-dose chemotherapy and ASCT. The median PFS for all 16 patients, however, was 12 weeks (range 3-212 þ ) (Figure 1 ) and the median overall survival for 15 patients in whom it is known was 72 weeks (range 3-252 þ ) (Figure 1 ). Thus, of the 16 patients who ASCT not effective in recurrent ALK-negative ALCL KW Zamkoff et al underwent high-dose therapy and ASCT for recurrent ALK-negative ALCL, 10 have died, five are alive and one is lost to follow-up. Nine of the 10 patients who died had recurrent disease at the time of death. One patient succumbed to secondary AML and had no recurrent disease at autopsy. Of the five living patients, only one is alive free of disease, 6 years post transplant. The four remaining surviving patients have all relapsed and have received additional salvage therapies.
Discussion
The current report has attempted to determine if high-dose therapy and ASCT results in long-term DFS for patients with recurrent ALK-negative ALCL. All reported series to date of high-dose therapy and ASCT in patients with either peripheral T-cell lymphomas, which have included patients with ALCL, or more specifically, series of patients with only ALCL, have not stratified ALCL patients by ALK status. [7] [8] [9] [13] [14] [15] The majority of patients with ALCL have tumors that express the ALK protein, so these series would be anticipated to contain a large proportion of ALKpositive patients, and may explain the extremely good results after high-dose therapy and ASCT in these ALCL patients compared to the patients in the present report.
The prognosis for patients with ALK-negative ALCL treated with anthracycline containing combination chemotherapy is significantly inferior compared to patients with ALK-positive ALCL. 5, 6 The only clinical feature that distinguishes between ALK-positive and -negative patients is age, with the ALK-positive group being much younger with a mean age of o30 years old, while the mean age for the ALK-negative patients is approximately 45 years. 5 Our series of patients with relapsed ALK-negative ALCL had a median age of 51 years old, which is in keeping with other reported series. There was a marked male predominance, with 11 of the 16 patients being male. All patients underwent transplant after their initial relapse.
IPI index has been reported to correlate well with longterm outcome in a group of 288 patients with peripheral T-cell lymphoma, 21% of whom had ALCL (but ALK status not mentioned) treated with anthracycline containing combination chemotherapy. Patients with 0 or 1 adverse IPI feature had an approximately 70% overall survival. 16 The poor prognosis of the current group of patients undergoing ASCT after initial relapse suggests that either a favorable IPI score at diagnosis or at the time of relapse or the demonstration of chemotherapy-sensitive relapse do not predict for prolonged DFS in ALK-negative ALCL, as they do in either in diffuse large B-cell lymphoma (DLBCL) or in other peripheral T-cell lymphomas.
In this series, there was only one long-term disease-free survivor. A second patient died of chemotherapy-induced MDS/AML approximately 250 weeks post-ASCT for recurrent ALCL, and was lymphoma free at post mortem. Thus, 14/16 patients with recurrent, chemotherapy-sensitive ALK-negative ALCL relapsed after high-dose therapy and ASCT, with a median PFS of 12 weeks.
The molecular mechanisms producing both the poor outcome after standard induction chemotherapy and, now as described in this report, after-high dose therapy and ASCT at relapse, in ALK-negative ALCL are unknown. Several recent papers have looked at the apoptotic pathway in patients with both ALK-negative and -positive ALCL and have revealed several important differences. In one series of 66 ALCL patients (45 ALK negative, 21 ALK positive), the ALK-negative tumors had significantly higher expression of the antiapoptotic proteins BCL-2 and BCL-XL and a significantly lower apoptotic rate than did the ALK-positive tumors. The proapoptotic proteins BAX and BCL-XS were expressed at correspondingly higher levels in the ALK-positive group. There was, however, no statistically significant association of BCL-2 family protein expression, when correlated with PFS. 17 In a series of 64 patients from the Netherlands (39 ALK negative, 25 ALK positive) no difference in clinical features between the ALK-positive and -negative groups other than older age in ALK-negative patients was observed. In this analysis, three molecules related to apoptosis were studied: the apoptosis effector active caspase-3, the antiapoptotic protein BCL-2 and the inhibitor of granzyme B-induced apoptosis protease inhibitor 9 (PI9). The overexpression of both BCL-2 and PI9 both were significantly correlated with decreased overall survival, while the overexpression of active caspase-3 was correlated with a significantly improved overall survival. The ALK-negative patients, in a statistically significant fashion, overexpressed BCL-2 and PI9, while having statistically less active caspase-3 expression in their tumors compared to the ALK-positive patients. For all patients, ALK status and percentage of BCL-2-positive cells were the two most important variables in determining overall survival. However, within the ALKnegative group, high BCL-2 and PI9 expression and low active caspase-3 expression revealed highly statistically significant decreases in overall survival. 18 ALK-negative ALCL, although defined by the expression of CD30, is both clinically and biologically different than ALK-positive ALCL. The current study has demonstrated a dismal salvage of patients with relapsed, but chemotherapy-sensitive ALK-negative ALCL with highdose therapy and ASCT. Since patients with ALK-negative ALCL have a very high relapse rate and poor overall survival when treated initially with anthracycline containing combination chemotherapy, alternative therapeutic strategies for ALK-negative ALCL at the time of diagnosis are needed. Unlike the situation with DLBCL, where the use of anti-CD20 monoclonal antibody in conjunction with combination chemotherapy may be altering the natural history of disease and improving patient survival, to date there have been no anti-T-cell monoclonal antibodies or biologic therapies that have been as successful for aggressive post-thymic lymphomas. 19 It has been shown that ALCLs express IL-2 receptor when determined on frozen tissue. 20 However, this earlier report did not stratify pathological material by the ALK status, and recently ALK-negative ALCL has been demonstrated not to express CD25, the high-affinity IL-2 receptor. 21 Thus, targeting CD25 with agents such as denileukin difitox (anti-CD25 bound to diphtheria toxin) may not be appropriate strategy in ALK-negative ALCL.
The appropriate management of patients with ALKnegative ALCL at diagnosis remains problematic. To date, there has not been a trial of aggressive induction therapy designed to achieve a durable initial CR, followed by consolidation with high-dose therapy and ASCT while in CR-1. In our experience, as the present data clearly shows, high-dose therapy and ASCT after relapse does not produce long-term DFS. However, until monoclonal antibody therapy directed at CD30 and/or a small molecule therapy targeted to overcome aberrations in the apoptotic pathway can be demonstrated to improve the outcome when used in conjunction with combination chemotherapy, as has been shown in DLBCL, a trial of high-dose therapy and ASCT following dose intense induction therapy designed to achieve a high level of durable initial CR, seems warranted.
